000043646 001__ 43646 000043646 005__ 20240822134915.0 000043646 0247_ $$2doi$$a10.6083/bpxhc43646 000043646 037__ $$aIR 000043646 041__ $$aeng 000043646 245__ $$aNanoparticles co-delivering doxorubicin & pd-l1 inhibitor to induce immunogenic cell death and enhance anti-cancer immune response in lung cancer 000043646 260__ $$bOregon Health and Science University 000043646 269__ $$a2024 000043646 336__ $$aAbstract 000043646 520__ $$aNon-small cell lung cancer (NSCLC) accounts for one in five of all cancer deaths worldwide. Most patients are diagnosed at advanced stages, resulting in a 5-year survival rate of less than 20%. Recently, immune checkpoint inhibitors (ICIs) for PD-L1 and PD-1 have received FDA approval for the treatment of NSCLC. However, only a small subset of patients (15-20%) respond to ICIs, and many of these responders eventually relapse. Doxorubicin (DOX) is an FDA-approved chemotherapeutic used in treating many cancers, including lung cancer. However, it has dose-dependent toxicity and patients develop resistance to DOX over time. 000043646 540__ $$fCC BY 000043646 542__ $$fIn copyright - joint owners 000043646 650__ $$aImmunogenic Cell Death$$013013 000043646 650__ $$aB7-H1 Antigen$$039834 000043646 650__ $$aDoxorubicin$$018045 000043646 650__ $$aLung Neoplasms$$021651 000043646 650__ $$aCarcinoma, Non-Small-Cell Lung$$016124 000043646 650__ $$aImmune Checkpoint Inhibitors$$013296 000043646 6531_ $$aPD-L1 000043646 6531_ $$alung cancer 000043646 691__ $$aSchool of Medicine$$041369 000043646 692__ $$aDepartment of Biomedical Engineering$$041397 000043646 7001_ $$aKumar, Pramod$$uOregon Health and Science University$$041354 000043646 7001_ $$aWallstrum, Alyssa$$uOregon Health and Science University$$041354 000043646 7001_ $$aReda, Moataz$$uOregon Health and Science University$$041354 000043646 7001_ $$aWang, Ruijie$$uOregon Health and Science University$$041354 000043646 7001_ $$aNgamcherdtrakul, Worapol$$uOregon Health and Science University$$041354 000043646 7001_ $$aYantasee, Wassana$$uOregon Health and Science University$$041354 000043646 711__ $$aResearch Week$$uOregon Health and Science University$$d2024 000043646 8564_ $$91130c9cf-b7c8-4c82-8aff-392734f61887$$s185632$$uhttps://digitalcollections.ohsu.edu/record/43646/files/ResearchWeek.2024.Kumar.Pramod.pdf 000043646 980__ $$aResearch Week